174 related articles for article (PubMed ID: 32930115)
1. Definitive concurrent chemoradiotherapy outcomes in Stage IIIB nonsmall cell lung cancer patients younger than 45 years: A retrospective analysis of 145 patients.
Topkan E; Guler OC; Ozdemir Y
J Cancer Res Ther; 2020; 16(4):757-763. PubMed ID: 32930115
[TBL] [Abstract][Full Text] [Related]
2. Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients.
Topkan E; Parlak C; Selek U
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):697-704. PubMed ID: 24035331
[TBL] [Abstract][Full Text] [Related]
3. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients.
Topkan E; Ozdemir Y; Kucuk A; Besen AA; Mertsoylu H; Sezer A; Selek U
PLoS One; 2019; 14(7):e0218627. PubMed ID: 31329602
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
[TBL] [Abstract][Full Text] [Related]
5. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
[TBL] [Abstract][Full Text] [Related]
6. Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
Topkan E; Parlak C; Topuk S; Pehlivan B
BMC Cancer; 2012 Oct; 12():502. PubMed ID: 23113946
[TBL] [Abstract][Full Text] [Related]
7. Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent Chemoradiation Therapy.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Besen AA; Findikcioglu A; Ozyilkan O
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1123-1132. PubMed ID: 29887509
[TBL] [Abstract][Full Text] [Related]
8. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of aggressive concurrent radiochemotherapy in highly selected septuagenarians with stage IIIB non-small cell lung carcinoma: retrospective analysis of 89 patients.
Topkan E; Parlak C; Topuk S; Guler OC; Selek U
Lung Cancer; 2013 Aug; 81(2):226-30. PubMed ID: 23726526
[TBL] [Abstract][Full Text] [Related]
10. Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.
Noh JM; Kim JM; Ahn YC; Pyo H; Kim B; Oh D; Ju SG; Kim JS; Shin JS; Hong CS; Park H; Lee E
Cancer Res Treat; 2016 Jan; 48(1):106-14. PubMed ID: 25687865
[TBL] [Abstract][Full Text] [Related]
11. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Mertsoylu H; Hahn SM
Lung Cancer; 2018 Jul; 121():30-36. PubMed ID: 29858023
[TBL] [Abstract][Full Text] [Related]
12. The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysis.
Lee HW; Choi JH; Lim HY; Park JS; Kim HC; Kang S; Oh YT; Chun M; Sheen SS; Oh YJ; Park KJ; Hwang SC
Neoplasma; 2006; 53(1):30-6. PubMed ID: 16416010
[TBL] [Abstract][Full Text] [Related]
13. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
[TBL] [Abstract][Full Text] [Related]
14. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
16. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
17. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
[TBL] [Abstract][Full Text] [Related]
18. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
20. Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience.
Yilmaz U; Yılmaz U; Yasar Z; Kıraklı EK; Ulger S; Ozdogan Y; Demirci NY; Erol S; Ozdogan I; Sahin B; Koksal D; Akcay C
J Cancer Res Ther; 2016; 12(1):334-9. PubMed ID: 27072260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
